 Connection
Daniel Sherbenou to Immunoconjugates
This is a "connection" page, showing publications Daniel Sherbenou has written about Immunoconjugates.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.691 |
|
|
|
-
Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 11 15; 26(22):6028-6038.
Score: 0.696
-
Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653.
Score: 0.534
-
Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91.
Score: 0.461
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|